Skip to content
Screener

Xencor XNCR Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$2.89M-44.6%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$445K-60.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$418K+186%
Regenxbio logo
RegenxbioRGNX
$442K-67.4%
Absci Corporation logo
Absci CorporationABSI
$328K-51.0%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+210%
Enterprise value$1.67B+150%
P/S14.7×+11.3×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(150,645)$(79,457)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization5,0075,346
Accretion of discount on marketable debt securities, net(135)(1,489)
Stock-based compensation18,75322,950
Loss (gain) on sale of marketable securities, net2(5,380)
Change in fair value of marketable equity securities33,865(528)
Asset impairment charges7976,723

Item 1. Financial Statements

FAQ

What is Xencor's accretion (amortization) of discounts and premiums, investments?
Xencor (XNCR) reported accretion (amortization) of discounts and premiums, investments of $7K in Q2 2026.
What is the long-term trend for Xencor's accretion (amortization) of discounts and premiums, investments?
Over 2 years (2021 to 2024), Xencor's accretion (amortization) of discounts and premiums, investments has grown at a 129.4% compound annual growth rate (CAGR), from -$3.16M to $16.64M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or accretion of discounts on debt securities held as investments. It reflects the gradual adjustment of the carrying value of investment securities toward their face value over time. Investors use this to reconcile the difference between the stated coupon rate and the effective yield of the investment portfolio.

Ask your AI about Xencor's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude